Kidney Disease News and Research

RSS

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

PLC Systems Inc., a company focused on innovative medical device technologies, announced that final results from the REMEDIAL II investigator-sponsored clinical trial of RenalGuard in Italy were presented today.

5 Apr 2011

Scientists reveal unknown role of cilia protein IFT88 in mitosis

Researchers at the University of Massachusetts Medical School have described a previously unknown role for the cilia protein IFT88 in mitosis, the process by which a dividing cell separates its chromosomes containing the cell's DNA into two identical sets of new daughter cells.

5 Apr 2011

KCP commends CMS for eliminating 'transition adjustment' imposed on new ESRD PPS

Kidney Care Partners, a broad-based coalition of patient advocates, dialysis professionals, care providers and manufacturers, commends the Centers for Medicare and Medicaid Services for eliminating the so-called "transition adjustment" imposed on dialysis facilities as part of the new Medicare end-stage renal disease prospective payment system.

2 Apr 2011

New CMS reimbursement system for ESRD may place cost constraints on clinics

According to Millennium Research Group, the global authority on medical technology market intelligence, the new reimbursement system from the Centers for Medicare & Medicaid Services for end stage renal disease will have a mixed but mostly negative effect on the market for ESRD treatment devices.

1 Apr 2011

First Edition: April 1, 2011

Today's health policy news coverage helps fill in the details of the much-anticipated rule for accountable care organizations, which was released yesterday by the Obama administration.

1 Apr 2011

NIH-funded program to focus on obesity complications in low-income mothers

A Michigan State University nursing researcher has been awarded $3.3 million to help low-income mothers who are overweight or obese improve their health by eating well, being active and dealing with stress.

1 Apr 2011

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its interim analysis and clinical update for CRMD001.

1 Apr 2011

Watson, GeneraMedix receive FDA approval for Nulecit to treat iron deficiency anemia

Watson Pharmaceuticals, Inc. today announced that it is initiating launch activities of Nulecit, following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application.

1 Apr 2011

Study: People who have survived diabetes for many decades exhibit few complications

Over time, diabetes can wreak havoc on the body's eyes, cardiovascular system, kidneys and nerves. A major study by Joslin Diabetes Center researchers, however, has found that some people who have survived diabetes for many decades exhibit remarkably few complications—a discovery that points toward the presence of protective factors that guard against the disease's effects.

31 Mar 2011

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC).

31 Mar 2011

Could HIV-infected organs save 'lives?

Johns Hopkins researchers argue for reversing ban on transplanting infected organs and making them available to HIV-infected patients

30 Mar 2011

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

30 Mar 2011

Stanford pediatrics receives Genzyme/ACMG award for biochemical genetic research

Anna-Kaisa Niemi, MD, Ph.D., a resident in Medical Genetics in the Department of Pediatrics, Division of Medical Genetics at the Stanford University Medical Center, in Stanford Calif., was honored as the 2011-2012 recipient of the Genzyme/American College of Medical Genetics Foundation Clinical Genetics Fellowship in Biochemical Genetics at the ACMG 2011 Annual Clinical Genetics Meeting in Vancouver, BC, Canada.

30 Mar 2011

Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes

Metabolic Solutions Development Company, a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has launched a Phase 2a trial for MSDC-0602, the company's second drug candidate for the treatment of type 2 diabetes.

30 Mar 2011

Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced it has made significant progress advancing CTP-499, its novel anti-inflammatory, anti-oxidant, and anti-fibrotic agent for diabetic nephropathy and other forms of chronic kidney disease, into clinical development.

29 Mar 2011

Interventional radiologists complete RDN human trial in patients with uncontrolled hypertension

Interventional radiologists have completed the first human randomized controlled trial of therapeutic renal denervation or RDN—a procedure that uses a catheter-based probe inserted into the renal artery that emits high-frequency energy to deactivate the nerves near the kidneys that are linked to high blood pressure.

29 Mar 2011

Tengion 2010 adjusted net loss decreases to $25.8 million

Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.

25 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced multiple posters on peginesatide have been accepted for presentation at the National Kidney Foundation 2011 Spring Clinical Meeting taking place April 26-30, 2011 in Las Vegas, Nevada.

24 Mar 2011

MicroRNAs may play a key role in future medicine

Since their discovery in the 1990s, microRNAs have proven to play a complex role in normal and abnormal functioning of many organ systems. In the April issue of Translational Research, entitled "MicroRNAs: A Potential New Frontier for Medicine," an international group of medical experts explores several themes related to our current understanding of microRNAs and the role they may play in the future of medicine.

24 Mar 2011

Kidney Disease News and Research

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

Scientists reveal unknown role of cilia protein IFT88 in mitosis

KCP commends CMS for eliminating 'transition adjustment' imposed on new ESRD PPS

New CMS reimbursement system for ESRD may place cost constraints on clinics

First Edition: April 1, 2011

NIH-funded program to focus on obesity complications in low-income mothers

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

Watson, GeneraMedix receive FDA approval for Nulecit to treat iron deficiency anemia

Study: People who have survived diabetes for many decades exhibit few complications

Amgen appeals EMA CHMP negative opinion on Vectibix-chemotherapy combination for wild-type KRAS mCRC

Could HIV-infected organs save 'lives?

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Stanford pediatrics receives Genzyme/ACMG award for biochemical genetic research

Metabolic Solutions initiates MSDC-0602 Phase 2a trial in patients with type 2 diabetes

Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy

Interventional radiologists complete RDN human trial in patients with uncontrolled hypertension

Tengion 2010 adjusted net loss decreases to $25.8 million

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting

MicroRNAs may play a key role in future medicine

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News